Drug Detail

Information about Erivedge

Generic Name
Vismodegib
IND
GDC-0449
Brand Name (US)
Erivedge
Manufacturer
Genentech
Drug Type
Delivery
Oral
Approval Status
Approved for a non-GIST cancer
Indications
Basal cell carcinoma-metastatic or recurrent
Overall Strategy
Strategy
Block related tumor signal paths
Drug Category
SMO inhibitor

Erivedge (vismodegib) is a drug that was approved in January, 2012, for the treatment of advanced basal cell carcinoma. It is not approved for use in GIST and


Links

 

Vismodegib - Wikipedia page
   

 

Erivedge.com (Genentech)
   

Trials of this drug


Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed